Foundation Medicine

Roche takes $1B majority stake in Foundation Medicine to use genomic testing to personalize oncology treatments

Monday, January 19, 2015

The quest for those patient populations that will benefit the most from spe­cific drugs and diagnostics has spurred Roche Holding, the world’s biggest seller of cancer drugs, to spend $1.03 billion for a majority stake in Foundation Medicine (FMI) to create a broad collaboration to advance the use of FMI’s genomic tests for solid tumors and blood cancers.

[Read More]

Roche to acquire majority ownership of Foundation Medicine

Monday, January 12, 2015

Foundation Medicine (FMI), based in Cambridge, Mass., and Roche will enter into a broad strategic collaboration to further advance Foundation Medicine’s position in molecular information and genomic analysis while providing Roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients. Roche also will acquire majority ownership of Foundation Medicine.

[Read More]

Foundation Medicine, Flatiron Health collaborate to develop data platform

Wednesday, December 3, 2014

Foundation Medicine, a molecular information company based in Cambridge, Mass., and Flatiron Health, a healthcare technology company headquartered in New York, have announced a strategic collaboration to develop a unique, proprietary cloud-based information platform combining genomic and clinical treatment and outcomes data to significantly advance the field of precision medicine for cancer.

[Read More]

Amgen joins NCI to accelerate development of personalized cancer treatments

Tuesday, June 17, 2014

Amgen will collaborate with the National Cancer Institute (NCI), part of the NIH, and other public and private sector partners, on the Lung Master Protocol (Lung-MAP), a new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol.

[Read More]

U.S. cancer researchers launching five-drug personalized medicines trial

Monday, April 21, 2014

U.S. cancer researchers plan to launch a five-drug clinical trial for patients with advanced lung cancer in mid-May, in a public-private collaboration between several major cancer organizations and five pharmaceutical companies that marks the second American multi-drug research program into personalized medicines to treat different cancers.

[Read More]